

CS/RMA-Q2(2025-2026)

November 05, 2025

To,
The Listing Department
BSE Limited
Department of Corporate Affairs
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

To,
The Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, Plot No. C/1, G Block
Bandra-Kurla Complex,
Bandra (E)
Mumbai - 400 051

Dear Sir/Madam,

Subject : Report of the Monitoring Agency with respect to utilization of proceeds raised through QIP by Azad Engineering Limited.

Reference: ISIN - INE02IJ01035; Scrip Id-544061; Scrip Code- AZAD

Pursuant to Regulation 173A of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 and Regulation 32 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the monitoring agency report issued by Care Ratings Limited, Monitoring Agency, in respect of utilization of proceeds raised through qualified institutions placement by the Company for the 2nd quarter ended September 30, 2025. The Audit Committee has reviewed and took note of the monitoring agency report through Audit Committee Meeting dated November 1, 2025.

The above said disclosure will also be hosted on the website of the Company at www.azad.in

You are requested to kindly take the same in your records.

Thanking you,

Yours truly,

For Azad Engineering Limited

Ful Kumar Gautam
Company Secretary & Compliance Officer
Membership No.: F13688

Encl.: As above

No. CARE/HRO/GEN/2025-26/1030

Board of Directors
Azad Engineering Limited
90/C, 90/D, Phase -1
I.D.A Jeedimetla,
Hyderabad
Telangana 500055

November 05, 2025

Dear Sir/Ma'am,

Monitoring Agency Report for the quarter ended September 30, 2025 - in relation to the QIP issue of Azad Engineering Limited ("the Company")

We write in our capacity of Monitoring Agency for the QIP Issue for the amount aggregating to ₹700.00 crore of the Company and refer to our duties cast under 82 of the Securities & Exchange Board of India (Issue of Capital & Disclosure Requirements) Regulations.

In this connection, we are enclosing the Monitoring Agency Report for the quarter ended September 30, 2025, as per aforesaid SEBI Regulations and Monitoring Agency Agreement dated February 25, 2025.

Request you to kindly take the same on record.

Thanking you,
Yours faithfully,



Niraj Thorat
Assistant Director
niraj.thorat@careedge.in

CARE Ratings Limited

401, Ashoka Scintilla, 3-6-520, Himayat Nagar,
Hyderabad - 500 029
Phone: +91-40-4010 2030

CIN-L67190MH1993PLC071691

4th Floor, Godrej Coliseum, Somaiya Hospital
Road, Off Eastern Express Highway, Sion (East),
Mumbai - 400 022
Phone: +91-22-6754 3456
Email: care@careedge.in • www.careedge.in

Report of the Monitoring Agency

Name of the issuer: Azad Engineering Ltd

For quarter ended: September 30, 2025

Name of the Monitoring Agency: CARE Ratings Limited

(a) Deviation from the objects: No

(b) Range of Deviation: Not applicable

Declaration:

We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal with any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013.

The MA or its affiliates may have a credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit-related analyses. We confirm that there is no conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer, or while undertaking credit rating or other commercial transactions with the entity.

We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title "Comments of the Board of Directors", that shall be captured by the Issuer's Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the issuer's Management/Board.



Signature:

Name and designation of the Authorized Signatory: Niraj Thorat

Designation of Authorized person/Signing Authority: Assistant Director

CARE Ratings Limited401, Ashoka Scintilla, 3-6-520, Himayat Nagar,
Hyderabad - 500 029
Phone: +91-40-4010 20304th Floor, Godrej Coliseum, Somaiya Hospital
Road, Off Eastern Express Highway, Sion (East),
Mumbai - 400 022
Phone: +91-22-6754 3456
Email: care@careedge.in • www.careedge.in

CIN-L67190MH1993PLC071691

1) Issuer Details:

Name of the issuer : Azad Engineering Limited
Name of the promoter : Rakesh Chopdar
Industry/sector to which it belongs : Industrial Manufacturing – Industrial Products

2) Issue Details

Issue Period : February 25, 2025, to March 03, 2025
Type of issue (public/rights) : QIP
Type of specified securities : Equity Shares
IPO Grading, if any : Not Applicable
Issue size (in crore) : ₹700.00 crore

3) Details of the arrangement made to ensure the monitoring of issue proceeds:

Particulars	Reply	Source of information / certifications considered by Monitoring Agency for preparation of report	Comments of the Monitoring Agency	Comments of the Board of Directors
Whether all utilization is as per the disclosures in the Offer Document?	Yes	CA certificate*, Bank statements, and offer document	Rs.376.71 crores have been utilized towards the objects of the placement, and the balance fund is maintained in Fixed Deposits, MA account and Escrow Account.	No comments received
Whether shareholder approval has been obtained in case of material deviations# from expenditures disclosed in the Offer Document?	NA	NA	NA	No comments received
Whether the means of finance for the disclosed objects of the issue have changed?	No	NA	NA	No comments received
Is there any major deviation observed over the earlier monitoring agency reports?	No	NA	No, there are no deviations observed from the last monitoring agency report	No comments received
Whether all Government/statutory approvals related to the object(s) have been obtained?	Yes	Management declaration	NA	No comments received
Whether all arrangements pertaining to technical assistance/collaboration are in operation?	NA	Management declaration	NA	No comments received
Are there any favorable/unfavorable events affecting the viability of these object(s)?	No	NA	No	No comments received
Is there any other relevant information that may materially affect the decision making of the investors?	No	NA	No	No comments received

* Chartered Accountant certificate from M/s Dagliya & Co Chartered Accountants dated October 28, 2025.



4) Details of objects to be monitored:

(i) Cost of objects –

Sr. No	Item Head	Source of information / certifications considered by Monitoring Agency for preparation of report	Original cost (as per the Offer Document) in Rs. Crore	Revised Cost in Rs. Crore	Comments of the Monitoring Agency	Comments of the Board of Directors		
						Reason for cost revision	Proposed financing option	Particulars of -firm arrangements made
1	Funding and part-funding the capital expenditure of our Company	Chartered Accountant certificate*, Final Prospectus, Placement Document	525.00	NA	NA	No comments received	No comments received	No comments received
2	General Corporate purposes	Chartered Accountant certificate*, Final Prospectus, Placement Document	156.21	NA	NA	No comments received	No comments received	No comments received
3	Issue Expenses	Chartered Accountant certificate*, Final Prospectus, Placement Document	18.79	NA	NA	No comments received	No comments received	No comments received
Total			700.00					

* Chartered Accountant certificate from M/s Dagliya & Co Chartered Accountants dated October 28, 2025.

NG

(ii) Progress in the objects –

Sr. No	Item Head	Source of information / certifications considered by Monitoring Agency for preparation of report	Amount as proposed in the Offer Document in Rs. Crore	Amount utilised in Rs. Crore			Total unutilised amount in Rs. crore	Comments of the Monitoring Agency	Comments of the Board of Directors	
				As at beginning of the quarter in Rs. Crore	During the quarter in Rs. Crore	At the end of the quarter in Rs. Crore			Reasons for idle funds	Proposed course of action
1	Funding and part-funding the capital expenditure of our Company	CA certificate*, Bank statements, Placement Document	525.00	85.31	128.37	213.68	311.32	The company utilized Rs.128.37 crore towards capex in line with placement document, during the quarter, with payments made through the monitoring account.	No comments received	No comments received
2	General Corporate purposes	CA certificate*, Bank statements, Placement Document	156.21	111.41	44.80	156.21	-	The company utilized Rs.44.80 crore during the quarter towards GCP, with payments routed from the monitoring account to the current account. In view of commingling of funds and large number of transactions in the current account, CARE Ratings has relied on CA Certificate, invoices and utilisation certificate shared by the company.	No comments received	No comments received
3	Issue Expenses	CA certificate*, Bank statements, Placement Document	18.79	6.11	0.71	6.82	11.97	The company utilized Rs.0.71 crore during the quarter towards issue expenses, with all payments made through the monitoring account.	No comments received	No comments received
Total			700.00	202.83	173.88	376.71	323.29			

* Chartered Accountant certificate from M/s Dagliya & Co Chartered Accountants dated October 28, 2025.

(iii) Deployment of unutilized proceeds:

Sr. No.	Type of instrument and name of the entity invested in	Amount invested	Maturity date	Earning	Return on Investment (%)	Market Value at the end of quarter
1.	Balance in Monitoring Agency Account	3.77	-	-	-	3.77
2.	Fixed Deposit, HDFC Bank	115.00	October 08, 2025	1.50	5.75	116.50
3.	Fixed Deposit, HDFC Bank	200.00	October 11, 2025	6.45	6.80	206.45
4.	Balance in Escrow Account	10.00	-	-	-	10.00
	Total unutilized proceeds (including interest income)	328.77		7.95		336.72
	Less: Interest earned on unutilized proceeds	5.48				
	Total unutilized proceeds (excl: interest income)	323.29				

NG

(iv) Delay in implementation of the object(s) –

Objects	Completion Date		Delay (no. of days/ months)	Comments of the Board of Directors	
	As per the offer document	Actual		Reason of delay	Proposed course of action
Funding capital expenditure	Over a period of two Fiscals by the end of FY2026	Ongoing	Timely progress is not ascertainable, as company has not shared any quarterly schedule of expenditure.	No comments received	No comments received
General Corporate Purposes (GCP)	Over a period of three Fiscals by the end of FY2027	H2FY26	NA	No comments received	No comments received
Issue Expenses	Not specified	Ongoing	NA	No comments received	No comments received

5) Details of utilization of proceeds stated as General Corporate Purpose (GCP) amount in the offer document:

Sr. No	Item Head^	Amount in Rs. Crore	Source of information / certifications considered by Monitoring Agency for preparation of report	Comments of Monitoring Agency	Comments of the Board of Directors
1	Salaries	8.50	Issuer Report	As per the offer document the company requires approval from Board or duly appointed committee to use funds for GCP. Such approval was not availed.	Report is approved at 01-11-2025, Board has taken note on comments on point 5 and is of view general corporate purposes may include, but are not restricted to, (i) investments in accordance with the investment policy of our Company, and (ii) meeting exigencies, salaries and meeting expenses incurred by our Company in the ordinary course of business. This is as per placement Document.
2	Vendor	31.51			
3	Others	4.79			
	Total	44.80			

^ Section from the offer document related to GCP:

"Our Company proposes to deploy the balance Net Proceeds aggregating to ₹1,562.10 million towards general corporate purposes and business requirements of our Company, subject to such amount not exceeding 25% of the gross proceeds of the Issue, in compliance with the SEBI ICDR Regulations. Such general corporate purposes may include, but are not restricted to, (i) investments in accordance with the investment policy of our Company, d (ii) meeting exigencies, salaries and meeting expenses incurred by our Company in the ordinary course of business as may be approved by the Board or a duly appointed committee from time to time, subject to compliance with the necessary provisions of the Companies Act, 2013, incurred by our Company in the ordinary course of business, as may be applicable. Further, this portion of Net Proceeds may also be utilised to meet the shortfall in the Net Proceeds for the Objects set out above.

In addition to the above, our Company may utilise the Net Proceeds towards other expenditure considered expedient and as approved periodically by our Board, subject to compliance with necessary provisions of the Companies Act and other applicable laws. The quantum of utilisation of funds towards each of the above purposes will be determined by our Board, based on the amount available under this head and the business requirements of our Company, from time to time.

NG

Disclaimers to MA report:

- a) This Report is prepared by CARE Ratings Ltd (hereinafter referred to as "**Monitoring Agency/MA**"). The MA has taken utmost care to ensure accuracy and objectivity while developing this Report based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever.
- b) This Report has to be seen in its entirety; the selective review of portions of the Report may lead to inaccurate assessments. For the purpose of this Report, MA has relied upon the information provided by the management /officials/ consultants of the Issuer and third-party sources like statutory auditor/peer reviewed audit firm appointed by the Issuer believed by it to be accurate and reliable.
- c) Nothing contained in this Report is capable or intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The MA is also not responsible for any errors in transmission and specifically states that it, or its directors, employees do not have any financial liabilities whatsoever to the users of this Report.
- d) The MA and its affiliates do not act as a fiduciary. The MA and its affiliates also do not act as an expert to the extent defined under Section 2(38) of the Companies Act, 2013. While the MA has obtained information from sources it believes to be reliable, it does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives from statutory auditors (or from peer reviewed CA firms), lawyers, chartered engineers or other experts, and relies on in its reports.
- e) The MA or its affiliates may have other commercial transactions with the entity to which the report pertains. As an example, the MA may rate the issuer, or any debt instruments / facilities issued or proposed to be issued by the issuer that is subject matter of this report. The MA may receive separate compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors.

NG